In April 2022, the US Food and Drug Administration (FDA) published a draft guidance recommending the development of diversity plans in clinical research programs. This guidance provides biopharma and biotech companies with an understanding of what the plan should include to ensure participants from underrepresented racial and ethnic populations (Black or African American, Hispanic/Latino, Indigenous and Native American, Asian, Native Hawaiian/Pacific Islanders and other persons of color) are represented in US clinical trials.
Research shows that adequate representation of diverse populations in clinical trials provides data heterogeneity, reflects real world patient populations, and can identify safety and efficacy outcomes that may be associated within certain groups. By incorporating diversity plans into drug development strategies we can strive to address these issues.
In this webinar, hear:
- What diversity and inclusion in clinical trials means, from a US and a global perspective
- What exactly is the FDA’s diversity plan and what should be included in it
- What are some important factors to consider when evaluating sites and patient recruitment partners supporting diverse enrollment
- Examples of successful case studies and strategies used to outperform studies diversity goals
Register for this webinar to learn more about innovative steps towards improving diversity in clinical trials.
Dustin Owen, Senior Vice President and General Manager, Accelerated Enrollment Solutions
Dustin Owen serves as Senior Vice President and General Manager of Accelerated Enrollment Solutions (AES), a PPD site conduct and patient enrollment business that includes a global network of more than 160 research sites spanning five continents and 16 countries. In this role, he is responsible for overseeing AES’ strategic direction, global operations and financial growth.
Dustin joined PPD in 2013 as Executive Director of Strategic Laboratory Operations and was promoted to Vice President of that function in 2016. Prior to his current position, Dustin served as Vice President of Clinical Operations and Head of PPD’s Asia-Pacific (APAC) region. He also serves as a board member of the PPD-SNBL joint venture in Japan.
Prior to PPD, Dustin’s experience included laboratory services and supply chain consulting for a variety of industries, including pharmaceuticals, while working in the US, Europe and APAC.
Dustin earned a Bachelor of Science in Industrial Engineering from the Georgia Institute of Technology and a Master of Business Administration from Duke University.Message Presenter
Brittany Erana, SVP Digital and Decentralized Solutions, PPD, Part of Thermo Fisher Scientific
Brittany Erana is Senior Vice President and Global Head of The Digital and Decentralized Solutions Group. In this role, she is responsible for setting the vision, developing and operationalizing new digital and decentralized trial capabilities — capabilities that span from clinical research operations to data collection, to patient & caregiver experience.
Brittany joined PPD in 2019 and brings more than 15 years of industry experience in global research operations and eClinical product strategy. Prior to joining PPD, Brittany was the Global Head of Operations for Patient-Centered Science and Technology at a CRO where she spent nine years conceptualizing and leading the development of new operational and technology capabilities through a combination of build, buy and partnering strategies.
Brittany has been recognized as a Triangle Business Journal 2021 40 under 40 Leader for inspiring people in life sciences. She holds a Bachelor of Arts in Psychology from East Carolina University, a master’s degree in project management from Western Carolina University and a certificate in international business from University College Dublin Smurfit Business School
Lloryn Hubbard, Associate Director Patient Solutions, PPD, Part of Thermo Fisher Scientific
Lloryn received her BA in biology and cultural anthropology from Seattle University. She started her career in diagnostic development, specifically low-cost diagnostic methods for developing countries. She moved into clinical operations where she had various clinical trial management roles for over a decade at various biotech and pharmaceutical companies including Roche/Genentech. In 2019 she moved into a Project Lead role in Global Health Equity and Population Science at Roche/Genentech where she was dedicated to supporting and finding solutions for inclusive research.
In 2021 she moved to PPD as Associate Director, Patient Diversity to further the work of advancing inclusive research. In the same year, she was also listed by Woman of Community on their “40 WOC Crushing It List” — highlighting 40 women of color working for the health of their communities.Message Presenter
Who Should Attend?
This webinar will appeal to:
- Industry: Biopharma and biotech companies involved in site and patient recruitment for clinical research
- Clinical research sites: Investigators and Site Directors of clinical research sites
- Healthcare providers: Clinicians involved in the management of clinical research patients
What You Will Learn
Attendees will gain insights into:
- Definitions of diversity and inclusion and how they can impact clinical research
- New US Food and Drug Administration (FDA) guidance and elements of a diversity plan
- Important factors to consider when evaluating potential site and patient recruitment vendors from the diversity perspective
Accelerated Enrollment Solutions (AES)
Accelerated Enrollment Solutions (AES) helps biopharmaceutical companies overcome patient enrollment and research site challenges by combining a powerful patient recruiting solution with more than 160 clinical research sites located throughout the world. As a business of PPD, we are committed to optimizing each step in the patient journey and delivering best-in-class site performance to bring our customers greater certainty to clinical trial delivery.